PT

Philip Tom

EVP & Chief Financial Officer at Avertix

New York, New York

Advisor

Invests in

Stages:

Seed
Pre-seed

  • Min Investment:

    $0.00

  • Max Investment:

    $0.00

  • Target Investment:

    $0.00

Skills

Budgeting
Analysis
Investment Banking
Policy
Economics

Education

Lists including Philip

AM
AR
AG
AH

Based in NYC

2600 people

AM
AT
AS
AR

All Seed Investors

19695 people

AT
AE
AE
AL

All Pre-Seed Investors

7974 people

Work Experience

AM
Avertix Medical

2023

  • Executive Vice President & Chief Financial Officer

    2023

    Avertix is a cutting-edge medical device company offering the first and only FDA-approved Class III implantable device that can detect silent and atypical symptomatic heart attacks in real-time. With a robust portfolio of U.S. patents pertaining to Acute Coronary Syndrome (ACS) events, Avertix is at the forefront of innovation in cardiovascular care and is committed to improving patient outcomes and saving lives through advanced medical technologies. For more information, visit avertix.com.

Explorer Acquisitions

2020 - 2023

  • Principal

    2020 - 2023

    Serial SPAC sponsor

HM
Hudson MX

2018 - 2020

  • CFO

    2018 - 2020

IV
Insight Venture Partners

2014 - 2018

  • Investment Team

    2014 - 2018

    Buyouts and majority recapitalizations in both high-growth and mature software businesses

CS
Credit Suisse

2012 - 2014

  • Investment Banking Associate

    2012 - 2014